Small Molecule Erythropoietin Mimetic Development for Stroke

Erythropoietin (EPO) is a occurs naturally hormone and cytokine in the human body. The erythropoietin receptor (EpoR) secretes erythropoietin, which exerts neuroprotective effects in the human body. Erythropoietin works by inhibiting apoptosis. It stimulates Janus tyrosine kinase through signaling pathways that lead to the expression of extracellular regulated kinases, Bcl-2, nuclear factor-κ, and protein kinases. Researchers consider it a viable candidate for the treatment of ischemic stroke because the molecule is small enough to easily cross the blood-brain barrier.

Fig.1. rhEPO treatment attenuates cellular alterations resulted from ischemic stroke. (Ma, et al., 2022)

Our Small Molecule Erythropoietin Mimetic Development Services

At Ace Therapeutics, we recognize the potential of erythropoietin in stroke therapy. We take a multidisciplinary approach, combining expertise in molecular biology, pharmacology and medicinal chemistry to help clients develop nonhematopoietic EPO mimetics. We provide valuable information on erythropoietin and its derivatives for the treatment of ischemic stroke and accelerate their preclinical development.

Design and Optimization of Small Molecule Erythropoietin Mimetics

Modifying the structure of erythropoietin. We can identify key amino acid residues in the EPO structure that are responsible for hematopoietic and neuroprotective activities. Targeted mutations or chemical modifications are introduced at these sites to selectively disrupt hematopoiesis while retaining neuroprotective properties.

Preclinical Evaluation of Small Molecule Erythropoietin Mimetics

We offer in vitro BBB models and animal models of stroke to evaluate the neuroprotective activity of non-hematopoietic EPO mimetics. In addition, we can help you tailor the different doses, routes of administration, and durations of administration of these drugs for the treatment of ischemic stroke models to ensure maximum efficacy.

• Erythropoietic activity assay
• Cellular uptake assay
• Endocytic transport assay
• In vivo distribution studies of small molecule erythropoietin mimetics
• In vivo neuroprotection studies of small molecule erythropoietin mimetics

Our Advantages

• Our multidisciplinary teams work closely together to leverage their expertise to design and optimize erythropoietin molecules for stroke therapy.
• From advanced computational modeling and protein engineering techniques to sophisticated in vitro and in vivo evaluation methods, we employ the latest tools and technologies to accelerate the development process and ensure high-quality results.
• We offer customized solutions for small molecule erythropoietin mimetic development to meet specific requirements.
• Our team of formulation scientists works closely with clients to develop innovative delivery systems for erythropoietin molecules.

At Ace Therapeutics, we pride ourselves on our commitment to excellence and innovation in stroke drug development. We are your trusted partner for comprehensive services in the development of EPO mimetics for the treatment of stroke. If you are interested in our services, please do not hesitate to contact us!

1. Ma, Y., et al. (2022). The effect of erythropoietin and its derivatives on ischemic stroke therapy: a comprehensive review. Frontiers in Pharmacology, 13, 743926.